Therapeutic Effects of Statins: Promising Drug for Topical and Transdermal Administration


Cite item

Full Text

Abstract

Statins are HMG-CoA reductase inhibitors and decrease plasma low-density lipoprotein cholesterol (LDL-C) levels. They are well tolerated, and because of their LDL-C-lowering effect, they are utilized to decrease the risk of atherosclerosis and cardiovascular disease. However, statins have pleiotropic effects, including immunomodulatory, anti-inflammatory, antioxidant, and anticancer. Currently, oral administration is the only Food and Drug Administration (FDA)-approved route of administration for statins. However, other administration routes have demonstrated promising results in different pre-clinical and clinical studies. For instance, statins also seem beneficial in dermatitis, psoriasis, vitiligo, hirsutism, uremic pruritus, and graft-versus-host disease. Topically applied statins have been studied to treat seborrhea, acne, rhinophyma, and rosacea. They also have beneficial effects in contact dermatitis and wound healing in animal studies, (HIV) infection, osseointegration, porokeratosis, and some ophthalmologic diseases. Topical and transdermal application of statins is a non-invasive drug administration method that has shown significant results in bypassing the first-pass metabolism in the liver, thereby reducing possible adverse effects. This study reviews the multifaceted molecular and cellular impacts of statins, their topical and transdermal application, novel delivery systems, such as nanosystems for topical and transdermal administration and the challenges concerning this approach.

About the authors

Fatemeh Zahedipour

Student Research Committee, Faculty of Medicin, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Seyede Hosseini

Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Željko Reiner

Department of Internal medicine, University Hospital Center Zagreb

Email: info@benthamscience.net

Eugenia Tedeschi-Reiner

, University Hospital Sestre Milosrdnice

Email: info@benthamscience.net

Tannaz Jamialahmadi

Applied Biomedical Research Center, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Amirhossein Sahebkar

Applied Biomedical Research Center, Mashhad University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Bedi, O.; Dhawan, V.; Sharma, P.L.; Kumar, P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch. Pharmacol., 2016, 389(7), 695-712. doi: 10.1007/s00210-016-1252-4 PMID: 27146293
  2. Bahrami, A.; Bo, S.; Jamialahmadi, T.; Sahebkar, A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res. Rev., 2020, 58, 101024. doi: 10.1016/j.arr.2020.101024 PMID: 32006687
  3. Bland, A.R.; Payne, F.M.; Ashton, J.C.; Jamialahmadi, T.; Sahebkar, A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol. Res., 2022, 175, 105986. doi: 10.1016/j.phrs.2021.105986 PMID: 34800627
  4. Ferretti, G.; Bacchetti, T.; Sahebkar, A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res., 2015, 60, 50-73. doi: 10.1016/j.plipres.2015.08.003 PMID: 26416579
  5. Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.; Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; Ferns, G.A.A. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids, 2011, 46(4), 333-340. doi: 10.1007/s11745-010-3517-x PMID: 21207250
  6. Sahebkar, A.; Chew, G.T.; Watts, G.F. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res. , 2014, 56(1), 47-66. doi: 10.1016/j.plipres.2014.07.002 PMID: 25083925
  7. Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-Like receptor pathways. Clinical reviews in allergy & immunology,, 2021, 60(2), 175–199. doi: 10.1007/s12016-020-08791-9
  8. Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Muntner, P.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.; Banach, M. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb. Haemost., 2015, 114(3), 546-557. PMID: 26017749
  9. Sohrevardi, S.; Nasab, F.; Mirjalili, M.; Bagherniya, M.; Tafti, A.; Jarrahzadeh, M.; Azarpazhooh, M.; Saeidmanesh, M.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch. Med. Sci., 2019, 17(5), 1423-1428. doi: 10.5114/aoms.2019.89330 PMID: 34522273
  10. Greenwood, J.; Steinman, L.; Zamvil, S.S. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat. Rev. Immunol., 2006, 6(5), 358-370. doi: 10.1038/nri1839 PMID: 16639429
  11. Davignon, J. Pleiotropic effects of pitavastatin. Br. J. Clin. Pharmacol., 2012, 73(4), 518-535. doi: 10.1111/j.1365-2125.2011.04139.x PMID: 22053916
  12. Viola, G.; Grobelny, P.; Linardi, M.A.; Salvador, A.; Dall’Acqua, S.; Sobotta, Ł.; Mielcarek, J.; Dall’Acqua, F.; Vedaldi, D.; Basso, G. Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts. Arch. Toxicol., 2012, 86(3), 483-496. doi: 10.1007/s00204-011-0772-4 PMID: 22038141
  13. Li, J.; Wang, Y.; Zhang, W.; Huang, Y.; Hein, K.; Hidalgo, I.J. The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. Drug Metab. Dispos., 2012, 40(11), 2102-2108. doi: 10.1124/dmd.112.045666 PMID: 22855735
  14. Bytyçi, I.; Penson, P.E.; Mikhailidis, D.P.; Wong, N.D.; Hernandez, A.V.; Sahebkar, A.; Thompson, P.D.; Mazidi, M.; Rysz, J.; Pella, D.; Reiner, Ž.; Toth, P.P.; Banach, M. Prevalence of statin intolerance: A meta-analysis. Eur. Heart J., 2022, 43(34), 3213-3223. doi: 10.1093/eurheartj/ehac015 PMID: 35169843
  15. Ward, N.C.; Watts, G.F.; Eckel, R.H. Statin toxicity. Circ. Res., 2019, 124(2), 328-350. doi: 10.1161/CIRCRESAHA.118.312782 PMID: 30653440
  16. Banach, M.; Serban, C.; Ursoniu, S.; Rysz, J.; Muntner, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.P.; Watts, G.F.; Blumenthal, R.S.; Lip, G.Y.H.; Mikhailidis, D.P.; Sahebkar, A. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res., 2015, 99, 329-336. doi: 10.1016/j.phrs.2015.07.008 PMID: 26192349
  17. Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2(7), 517-526. doi: 10.1038/nrd1112 PMID: 12815379
  18. Reiner, Ž. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol., 2013, 10(8), 453-464. doi: 10.1038/nrcardio.2013.80 PMID: 23736519
  19. Ostrowski, S.M.; Johnson, K.; Siefert, M.; Shank, S.; Sironi, L.; Wolozin, B.; Landreth, G.E.; Ziady, A.G. Simvastatin inhibits protein isoprenylation in the brain. Neuroscience, 2016, 329, 264-274. doi: 10.1016/j.neuroscience.2016.04.053 PMID: 27180285
  20. Abrahamson, E.E.; Ikonomovic, M.D.; Dixon, C.E.; DeKosky, S.T. Simvastatin therapy prevents brain trauma-induced increases in β-amyloid peptide levels. Ann. Neurol., 2009, 66(3), 407-414. doi: 10.1002/ana.21731 PMID: 19798641
  21. Ostad, S.N.; Afzali, M.; Vatankhah, M. Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7. J. Cancer Res. Ther., 2016, 12(2), 725-730. doi: 10.4103/0973-1482.146127 PMID: 27461641
  22. Kim, Y.; Kim, T.W.; Han, S.W.; Ahn, J.B.; Kim, S.T.; Lee, J.; Park, J.O.; Park, Y.S.; Lim, H.Y.; Kang, W.K. A single arm, phase II study of simvastatin plus XELOX and bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients. Cancer Res. Treat., 2019, 51(3), 1128-1134. doi: 10.4143/crt.2018.379 PMID: 30477287
  23. Li, N.; Xie, X.; Hu, Y.; He, H.; Fu, X.; Fang, T.; Li, C. Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am. J. Transl. Res., 2019, 11(3), 1255-1269. PMID: 30972160
  24. Luput, L.; Sesarman, A.; Porfire, A.; Achim, M.; Muntean, D.; Casian, T.; Patras, L.; Rauca, V.F.; Drotar, D.M.; Stejerean, I.; Tomuta, I.; Vlase, L.; Dragos, N.; Toma, V.A.; Licarete, E.; Banciu, M. Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci., 2020, 111(4), 1344-1356. doi: 10.1111/cas.14312 PMID: 31960547
  25. Lin, T-K; Chou, P; Lin, C-H; Hung, Y-J; Jong, G-P Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. PLoS One, 2018, 13(5), e0196713.
  26. Leutner, M.; Matzhold, C.; Bellach, L.; Deischinger, C.; Harreiter, J.; Thurner, S.; Klimek, P.; Kautzky-Willer, A. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann. Rheum. Dis., 2019, 78(12), 1706-1711. doi: 10.1136/annrheumdis-2019-215714 PMID: 31558481
  27. Blackman, A.L.; Pandit, N.S.; Pincus, K.J. Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients. HIV Med., 2020, 21(3), 135-141. doi: 10.1111/hiv.12794 PMID: 31876122
  28. Jowkar, F.; Namazi, M.R. Statins in dermatology. Int. J. Dermatol., 2010, 49(11), 1235-1243. doi: 10.1111/j.1365-4632.2010.04579.x PMID: 20964647
  29. Kellesarian, S.; Al Amri, M.; Al-Kheraif, A.; Ghanem, A.; Malmstrom, H.; Javed, F. Efficacy of local and systemic statin delivery on the osseointegration of implants: A systematic Review. Int. J. Oral Maxillofac. Implants, 2017, 32(3), 497-506. doi: 10.11607/jomi.4955 PMID: 28494034
  30. Dundar, S.; Bozoglan, A. Evaluation of the effects of topically applied simvastatin on titanium implant osseointegration. J. Oral Biol. Craniofac. Res., 2020, 10(2), 149-152. doi: 10.1016/j.jobcr.2020.04.004 PMID: 32322477
  31. Atzmony, L.; Lim, Y.H.; Hamilton, C.; Leventhal, J.S.; Wagner, A.; Paller, A.S.; Choate, K.A. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. J. Am. Acad. Dermatol., 2020, 82(1), 123-131. doi: 10.1016/j.jaad.2019.08.043 PMID: 31449901
  32. Auger, F.A.; Lacroix, D.; Germain, L. Skin substitutes and wound healing. Skin Pharmacol. Physiol., 2009, 22(2), 94-102. doi: 10.1159/000178868 PMID: 19188757
  33. Bellosta, S.; Fed, N.; Bernini, F.; Paoletti, R.; Corsini, A. Non-lipid-related effects of statins. Ann. Med., 2000, 32(3), 164-176. doi: 10.3109/07853890008998823 PMID: 10821323
  34. Williams, D.; Feely, J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet., 2002, 41(5), 343-370. doi: 10.2165/00003088-200241050-00003 PMID: 12036392
  35. Šimić, I.; Reiner, Z. Adverse effects of statins - myths and reality. Curr. Pharm. Des., 2015, 21(9), 1220-1226. doi: 10.2174/1381612820666141013134447 PMID: 25312733
  36. Reiner, Ž. Resistance and intolerance to statins. Nutr. Metab. Cardiovasc. Dis., 2014, 24(10), 1057-1066. doi: 10.1016/j.numecd.2014.05.009 PMID: 24996502
  37. Kaur, R.; Ajitha, M. Transdermal delivery of fluvastatin loaded nanoemulsion gel: Preparation, characterization and in vivo anti-osteoporosis activity. Eur. J. Pharm. Sci., 2019, 136, 104956. doi: 10.1016/j.ejps.2019.104956 PMID: 31202895
  38. Prueksaritanont, T.; Gorham, L.M.; Ma, B.; Liu, L.; Yu, X.; Zhao, J.J.; Slaughter, D.E.; Arison, B.H.; Vyas, K.P. In vitro metabolism of simvastatin in humans SBTidentification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos., 1997, 25(10), 1191-1199. PMID: 9321523
  39. Prueksaritanont, T.; Ma, B.; Yu, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol., 2003, 56(1), 120-124. doi: 10.1046/j.1365-2125.2003.01833.x PMID: 12848784
  40. Backman, J.T.; Filppula, A.M.; Niemi, M.; Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev., 2016, 68(1), 168-241. doi: 10.1124/pr.115.011411 PMID: 26721703
  41. Liu, Y.; Zeng, B.H.; Shang, H.T.; Cen, Y.Y.; Wei, H. Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: Comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin. Comp. Med., 2008, 58(6), 580-587. PMID: 19149415
  42. Li, M.; Fan, L.Y.; Zhang, W.; Cao, C.X. Stacking and quantitative analysis of lovastatin in urine samples by the transient moving chemical reaction boundary method in capillary electrophoresis. Anal. Bioanal. Chem., 2007, 387(8), 2719-2725. doi: 10.1007/s00216-007-1169-3 PMID: 17333149
  43. Liu, A.; Wu, Q.; Guo, J.; Ares, I.; Rodríguez, J.L.; Martínez-Larrañaga, M.R.; Yuan, Z.; Anadón, A.; Wang, X.; Martínez, M.A. Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacol. Ther., 2019, 195, 54-84. doi: 10.1016/j.pharmthera.2018.10.004 PMID: 30321555
  44. Sprecher, D.L.; Goodman, S.G.; Kannampuzha, P.; Pearce, G.L.; Langer, A. Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. Atherosclerosis, 2003, 171(2), 255-258. doi: 10.1016/S0021-9150(03)00290-9 PMID: 14644394
  45. Babita, K.; Tiwary, A. Skin lipid synthesis inhibition: A possible means for enhancing percutaneous delivery of levodopa. Curr. Drug Deliv., 2004, 1(4), 397-403. doi: 10.2174/1567201043334579 PMID: 16305401
  46. Brazzell, V.; Distante, F.; Perani, G.; Berardesca, E. Effects of systemic treatment with statins on skin barrier function and stratum corneum water-holding capacity. Dermatology, 1996, 192(3), 214-216. doi: 10.1159/000246368 PMID: 8726633
  47. Dobs, A.S.; Levine, M.A.; Margolis, S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism, 1991, 40(5), 524-528. doi: 10.1016/0026-0495(91)90235-O PMID: 1902546
  48. Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA, 2001, 286(1), 64-70. doi: 10.1001/jama.286.1.64 PMID: 11434828
  49. Musial, J.; Undas, A.; Gajewski, P.; Jankowski, M.; Sydor, W.; Szczeklik, A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol., 2001, 77(2-3), 247-253. doi: 10.1016/S0167-5273(00)00439-3 PMID: 11182189
  50. Albert, M.A.; Glynn, R.J.; Ridker, P.M. Plasma concentration of C-reactive protein and the calculated framingham coronary heart disease risk score. Circulation, 2003, 108(2), 161-165. doi: 10.1161/01.CIR.0000080289.72166.CF PMID: 12835213
  51. Mowla, K.; Rajai, E.; Ghorbani, A.; Dargahi-Malamir, M.; Bahadoram, M.; Mohammadi, S. Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: Double-blind randomized controlled trial. J. Clin. Diagn. Res., 2016, 10(5), OC32-OC36. doi: 10.7860/JCDR/2016/16538.7814 PMID: 27437268
  52. Nagashima, T.; Okazaki, H.; Yudoh, K.; Matsuno, H.; Minota, S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: A potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum., 2006, 54(2), 579-586. doi: 10.1002/art.21564 PMID: 16447234
  53. Palinski, W.; Tsimikas, S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J. Am. Soc. Nephrol., 2002, 13(6), 1673-1681. doi: 10.1097/01.ASN.0000018400.39687.8C PMID: 12039998
  54. Kittleson, M.M.; Kobashigawa, J.A. Statins in heart transplantation. Clin. Transpl., 2013, 135-143. PMID: 25095502
  55. Chataway, J.; Schuerer, N.; Alsanousi, A.; Chan, D.; Mac-Manus, D.; Hunter, K.; Anderson, V.; Bangham, C.R.M.; Clegg, S.; Nielsen, C.; Fox, N.C.; Wilkie, D.; Nicholas, J.M.; Calder, V.L.; Greenwood, J.; Frost, C.; Nicholas, R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet, 2014, 383(9936), 2213-2221. doi: 10.1016/S0140-6736(13)62242-4 PMID: 24655729
  56. Kamm, C.P.; El-Koussy, M.; Humpert, S.; Findling, O.; Bredow, F.; Burren, Y.; Schwegler, G.; Schött, D.; Donati, F.; Müller, M.; Goebels, N.; Müller, F.; Slotboom, J.; Tettenborn, B.; Kappos, L.; Naegelin, Y.; Mattle, H.P. Atorvastatin added to interferon β for relapsing multiple sclerosis: A randomized controlled trial. J. Neurol., 2012, 259(11), 2401-2413. doi: 10.1007/s00415-012-6513-7 PMID: 22569835
  57. Rego, A.C.M.; Araújo Filho, I.; Damasceno, B.P.G.L.; Egito, E.S.T.; Silveira, I.A.; Brandão-Neto, J.; Medeiros, A.C. Simvastatin improves the healing of infected skin wounds of rats. Acta Cir. Bras., 2007, 22(Suppl. 1), 57-63. doi: 10.1590/S0102-86502007000700012 PMID: 17505657
  58. Pruefer, D.; Makowski, J.; Schnell, M.; Buerke, U.; Dahm, M.; Oelert, H.; Sibelius, U.; Grandel, U.; Grimminger, F.; Seeger, W.; Meyer, J.; Darius, H.; Buerke, M. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation, 2002, 106(16), 2104-2110. doi: 10.1161/01.CIR.0000034048.38910.91 PMID: 12379581
  59. Otuki, M.F.; Pietrovski, E.F.; Cabrini, D.A. Topical simvastatin: Preclinical evidence for a treatment of skin inflammatory conditions. J. Dermatol. Sci., 2006, 44(1), 45-47. doi: 10.1016/j.jdermsci.2006.04.006 PMID: 16759838
  60. Jameel, A; Ooi, KG-J; Jeffs, NR; Galatowicz, G; Lightman, SL; Calder, VL Statin modulation of human T-cell proliferation, IL-1 and IL-17 production, and IFN-T cell expression: synergy with conventional immunosuppressive agents. Int. J. Inflamm., 2013, 2013
  61. Stüve, O.; Youssef, S.; Slavin, A.J.; King, C.L.; Patarroyo, J.C.; Hirschberg, D.L.; Brickey, W.J.; Soos, J.M.; Piskurich, J.F.; Chapman, H.A.; Zamvil, S.S. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J. Immunol., 2002, 169(12), 6720-6732. doi: 10.4049/jimmunol.169.12.6720 PMID: 12471103
  62. Sobrin, L.; Yu, Y.; Han, S.; Susarla, G.; Kempen, J.H.; Hubbard, R.A.; VanderBeek, B.L. Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database. Graefes Arch. Clin. Exp. Ophthalmol., 2021, 259(9), 2783-2793. doi: 10.1007/s00417-021-05243-8 PMID: 34050812
  63. Kim, Y.C.; Kim, K.K.; Shevach, E.M. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-β signal transduction. Immunology, 2010, 130(4), 484-493. doi: 10.1111/j.1365-2567.2010.03269.x PMID: 20408897
  64. Namazi, M.R. Statins: novel additions to the dermatologic arsenal? Exp. Dermatol., 2004, 13(6), 337-339. doi: 10.1111/j.0906-6705.2004.00208.x PMID: 15186318
  65. Dellavalle, R.P.; Drake, A.; Graber, M.; Heilig, L.F.; Hester, E.J.; Johnson, K.R.; McNealy, K.; Schilling, L. Statins and fibrates for preventing melanoma. Cochrane Database Syst. Rev., 2005, (4), CD003697. PMID: 16235336
  66. Guasti, L.; Marino, F.; Cosentino, M.; Maio, R.C.; Rasini, E.; Ferrari, M.; Castiglioni, L.; Klersy, C.; Gaudio, G.; Grandi, A.M.; Lecchini, S.; Venco, A. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur. Heart J., 2008, 29(9), 1118-1126. doi: 10.1093/eurheartj/ehn138 PMID: 18390537
  67. Goldstein, M.R.; Mascitelli, L.; Pezzetta, F. Statins, leptin and regulatory T cells. Nutr. Metab. Cardiovasc. Dis., 2008, 18(6), e27. doi: 10.1016/j.numecd.2008.01.001 PMID: 18450434
  68. Lim, S.; Barter, P. Antioxidant effects of statins in the management of cardiometabolic disorders. J. Atheroscler. Thromb., 2014, 21(10), 997-1010. doi: 10.5551/jat.24398 PMID: 25132378
  69. Sorrentino, S.; Landmesser, U. Nonlipid-lowering effects of statins. Curr. Treat. Options Cardiovasc. Med., 2005, 7(6), 459-466. doi: 10.1007/s11936-005-0031-1 PMID: 16283973
  70. Ajith, T.A.; Riji, T.; Anu, V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin. Exp. Pharmacol. Physiol., 2008, 35(5-6), 625-629. doi: 10.1111/j.1440-1681.2007.04853.x PMID: 18177480
  71. Vincent, T.S.; Wülfert, E.; Merler, E. Inhibition of growth factor signaling pathways by lovastatin. Biochem. Biophys. Res. Commun., 1991, 180(3), 1284-1289. doi: 10.1016/S0006-291X(05)81334-8 PMID: 1953779
  72. Louneva, N.; Huaman, G.; Fertala, J.; Jiménez, S.A. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum., 2006, 54(4), 1298-1308. doi: 10.1002/art.21723 PMID: 16575855
  73. Khoshneviszadeh, M.; Ashkani-Esfahani, S.; Namazi, M.R.; Noorafshan, A.; Geramizadeh, B.; Miri, R. Topical simvastatin enhances tissue regeneration in full-thickness skin wounds in rat models. Iran. J. Pharm. Res., 2014, 13(1), 263-269. PMID: 24734079
  74. Sawaya, A.P.; Pastar, I.; Stojadinovic, O.; Lazovic, S.; Davis, S.C.; Gil, J.; Kirsner, R.S.; Tomic-Canic, M. Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5. J. Biol. Chem., 2018, 293(4), 1439-1449. doi: 10.1074/jbc.M117.811240 PMID: 29158265
  75. Meyer-ter-Vehn, T.; Katzenberger, B.; Han, H.; Grehn, F.; Schlunck, G. Lovastatin inhibits TGF-β-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci., 2008, 49(9), 3955-3960. doi: 10.1167/iovs.07-1610 PMID: 18421080
  76. Kamio, K.; Liu, X.D.; Sugiura, H.; Togo, S.; Kawasaki, S.; Wang, X.; Ahn, Y.; Hogaboam, C.; Rennard, S.I. Statins inhibit matrix metalloproteinase release from human lung fibroblasts. Eur. Respir. J., 2010, 35(3), 637-646. doi: 10.1183/09031936.00134707 PMID: 19797126
  77. Oliver, M.F. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet, 1991, 337(8756), 1529-1531. doi: 10.1016/0140-6736(91)93208-Q PMID: 1675380
  78. Demierre, M.F.; Higgins, P.D.R.; Gruber, S.B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. Nat. Rev. Cancer, 2005, 5(12), 930-942. doi: 10.1038/nrc1751 PMID: 16341084
  79. Edwards, P.A.; Ericsson, J. Sterols and isoprenoids: Signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem., 1999, 68(1), 157-185. doi: 10.1146/annurev.biochem.68.1.157 PMID: 10872447
  80. Mo, H.; Elson, C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood), 2004, 229(7), 567-585. doi: 10.1177/153537020422900701 PMID: 15229351
  81. Safwat, S.; Ishak, R.A.; Hathout, R.M.; Mortada, N.D. Statins anticancer targeted delivery systems: re-purposing an old molecule. J. Pharm. Pharmacol., 2017, 69(6), 613-624. doi: 10.1111/jphp.12707 PMID: 28271498
  82. Bellosta, S.; Bernini, F.; Ferri, N.; Quarato, P.; Canavesi, M.; Arnaboldi, L.; Fumagalli, R.; Paoletti, R.; Corsini, A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 1998, 137(Suppl.), S101-S109. doi: 10.1016/S0021-9150(97)00319-5 PMID: 9694549
  83. Chan, K.K.; Oza, A.M.; Siu, L.L. The statins as anticancer agents. Clin. Cancer Res., 2003, 9(1), 10-19. PMID: 12538446
  84. Wright, R.S.; Murphy, J.G.; Bybee, K.A.; Kopecky, S.L.; LaBlanche, J.M. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: Efficacy and mechanism of benefit. Mayo Clin. Proc., 2002, 77(10), 1085-1092. doi: 10.4065/77.10.1085 PMID: 12374252
  85. Denoyelle, C.; Albanese, P.; Uzan, G.; Hong, L.; Vannier, J.P.; Soria, J.; Soria, C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell. Signal., 2003, 15(3), 327-338. doi: 10.1016/S0898-6568(02)00124-9 PMID: 12531431
  86. Rao, S.; Porter, D.C.; Chen, X.; Herliczek, T.; Lowe, M.; Keyomarsi, K. Lovastatin-mediated G 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA, 1999, 96(14), 7797-7802. doi: 10.1073/pnas.96.14.7797 PMID: 10393901
  87. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 2001, 7(6), 687-692. doi: 10.1038/89058 PMID: 11385505
  88. Pedersen, T.R.; Wilhelmsen, L.; Færgeman, O.; Strandberg, T.E.; Thorgeirsson, G.; Troedsson, L.; Kristianson, J.; Berg, K.; Cook, T.J.; Haghfelt, T.; Kjekshus, J.; Miettinen, T.; Olsson, A.G.; Pyörälä, K.; Wedel, H. Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol., 2000, 86(3), 257-262. doi: 10.1016/S0002-9149(00)00910-3 PMID: 10922429
  89. Ghosh-Choudhury, N.; Mandal, C.C.; Ghosh-Choudhury, N.; Ghosh Choudhury, G. Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth. Cell. Signal., 2010, 22(5), 749-758. doi: 10.1016/j.cellsig.2009.12.010 PMID: 20060890
  90. Katz, M.S. Therapy Insight: potential of statins for cancer chemoprevention and therapy. Nat. Clin. Pract. Oncol., 2005, 2(2), 82-89. doi: 10.1038/ncponc0097 PMID: 16264880
  91. Ghasemi, A.; Ghashghai, Z.; Akbari, J.; Yazdani-Charati, J.; Salehifar, E.; Hosseinimehr, S.J. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: A randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Pharmacol., 2019, 75(2), 171-178. doi: 10.1007/s00228-018-2570-x PMID: 30291370
  92. Capanema, N.S.V.; Carvalho, I.C.; Mansur, A.A.P.; Carvalho, S.M.; Lage, A.P.; Mansur, H.S. Hybrid hydrogel composed of carboxymethylcellulose–silver nanoparticles–doxorubicin for anticancer and antibacterial therapies against melanoma skin cancer cells. ACS Appl. Nano Mater., 2019, 2(11), 7393-7408. doi: 10.1021/acsanm.9b01924
  93. Akbarzadeh, I.; Keramati, M.; Azadi, A.; Afzali, E.; Shahbazi, R.; chiani, M.; Norouzian, D.; Bakhshandeh, H. Optimization, physicochemical characterization, and antimicrobial activity of a novel simvastatin nano-niosomal gel against E. coli and S. aureus. Chem. Phys. Lipids, 2021, 234, 105019. doi: 10.1016/j.chemphyslip.2020.105019 PMID: 33232724
  94. Malta, R.; Loureiro, J.B.; Costa, P.; Sousa, E.; Pinto, M.; Saraiva, L.; Amaral, M.H. Development of lipid nanoparticles containing the xanthone LEM2 for topical treatment of melanoma. J. Drug Deliv. Sci. Technol., 2021, 61, 102226. doi: 10.1016/j.jddst.2020.102226
  95. Suterio, N.; Bazzo, G.C.; Rauber, G.S.; Silva, A.H.; Caon, T.; Parize, A.L.; Creczynski-Pasa, T.B.; Stulzer, H.K. Laponite® gel formulation containing simvastatin for melanoma treatment. Appl. Clay Sci., 2022, 228, 106651. doi: 10.1016/j.clay.2022.106651
  96. Llevadot, J.; Asahara, T. Efecto de las estatinas en la inducción de angiogénesis y vasculogénesis. Rev. Esp. Cardiol., 2002, 55(8), 838-844. doi: 10.1016/S0300-8932(02)76713-4 PMID: 12199980
  97. Kureishi, Y.; Luo, Z.; Shiojima, I.; Bialik, A.; Fulton, D.; Lefer, D.J.; Sessa, W.C.; Walsh, K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med., 2000, 6(9), 1004-1010. doi: 10.1038/79510 PMID: 10973320
  98. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399(6736), 601-605. doi: 10.1038/21224 PMID: 10376603
  99. Fulton, D.; Gratton, J.P.; McCabe, T.J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T.F.; Papapetropoulos, A.; Sessa, W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 1999, 399(6736), 597-601. doi: 10.1038/21218 PMID: 10376602
  100. Vincent, L.; Chen, W.; Hong, L.; Mirshahi, F.; Mishal, Z.; Mirshahi-Khorassani, T.; Vannier, J.P.; Soria, J.; Soria, C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett., 2001, 495(3), 159-166. doi: 10.1016/S0014-5793(01)02337-7 PMID: 11334884
  101. Urbich, C.; Dernbach, E.; Zeiher, A.M.; Dimmeler, S. Double-edged role of statins in angiogenesis signaling. Circ. Res., 2002, 90(6), 737-744. doi: 10.1161/01.RES.0000014081.30867.F8 PMID: 11934843
  102. Asai, J.; Takenaka, H.; Hirakawa, S.; Sakabe, J.; Hagura, A.; Kishimoto, S.; Maruyama, K.; Kajiya, K.; Kinoshita, S.; Tokura, Y.; Katoh, N. Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am. J. Pathol., 2012, 181(6), 2217-2224. doi: 10.1016/j.ajpath.2012.08.023 PMID: 23138019
  103. Farsaei, S.; Khalili, H.; Farboud, E.S. Potential role of statins on wound healing: review of the literature. Int. Wound J., 2012, 9(3), 238-247. doi: 10.1111/j.1742-481X.2011.00888.x PMID: 22050652
  104. Simko, F.; Matuskova, J.; Luptak, I.; Krajcirovicova, K.; Kucharska, J.; Gvozdjakova, A.; Babal, P.; Pechanova, O. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci., 2004, 74(10), 1211-1224. doi: 10.1016/j.lfs.2003.07.032 PMID: 14697405
  105. Vukelic, S.; Stojadinovic, O.; Pastar, I.; Rabach, M.; Krzyzanowska, A.; Lebrun, E.; Davis, S.C.; Resnik, S.; Brem, H.; Tomic-Canic, M. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J. Biol. Chem., 2011, 286(12), 10265-10275. doi: 10.1074/jbc.M110.188268 PMID: 21239489
  106. Pastar, I.; Stojadinovic, O.; Sawaya, A.P.; Stone, R.C.; Lindley, L.E.; Ojeh, N.; Vukelic, S.; Samuels, H.H.; Tomic-Canic, M. Skin metabolite, farnesyl pyrophosphate, regulates epidermal response to inflammation, oxidative stress, and migration. J. Cell. Physiol., 2016, 231(11), 2452-2463. doi: 10.1002/jcp.25357 PMID: 26916741
  107. Lindley, L.E.; Stojadinovic, O.; Pastar, I.; Tomic-Canic, M. Biology and biomarkers for wound healing. Plast. Reconstr. Surg., 2016, 138(3)(Suppl.), 18S-28S. doi: 10.1097/PRS.0000000000002682 PMID: 27556760
  108. Stojadinovic, O.; Pastar, I.; Nusbaum, A.G.; Vukelic, S.; Krzyzanowska, A.; Tomic-Canic, M. Deregulation of epidermal stem cell niche contributes to pathogenesis of nonhealing venous ulcers. Wound Repair Regen., 2014, 22(2), 220-227. doi: 10.1111/wrr.12142 PMID: 24635172
  109. Toker, S.; Gulcan, E.; Çaycı, M.K.; Olgun, E.G.; Erbilen, E.; Özay, Y. Topical atorvastatin in the treatment of diabetic wounds. Am. J. Med. Sci., 2009, 338(3), 201-204. doi: 10.1097/MAJ.0b013e3181aaf209 PMID: 19667969
  110. Erdogan, S. Liposomal nanocarriers for tumor imaging. J. Biomed. Nanotechnol., 2009, 5(2), 141-150. doi: 10.1166/jbn.2009.1016 PMID: 20055092
  111. Prow, T.W.; Grice, J.E.; Lin, L.L.; Faye, R.; Butler, M.; Becker, W.; Wurm, E.M.T.; Yoong, C.; Robertson, T.A.; Soyer, H.P.; Roberts, M.S. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev., 2011, 63(6), 470-491. doi: 10.1016/j.addr.2011.01.012 PMID: 21315122
  112. Schmalfuß, U.; Neubert, R.; Wohlrab, W. Modification of drug penetration into human skin using microemulsions. J. Control. Release, 1997, 46(3), 279-285. doi: 10.1016/S0168-3659(96)01609-4
  113. Jia, S; Xie, P; Hong, SJ; Galiano, RD; Mustoe, TA Local application of statins significantly reduced hypertrophic scarring in a rabbit ear model. Plast. Reconstr. Surg. Glob. Open, 2017, 5(6), e1294. doi: 10.1097/GOX.0000000000001294
  114. Xie, P.; Dolivo, D.M.; Jia, S.; Cheng, X.; Salcido, J.; Galiano, R.D.; Hong, S.J.; Mustoe, T.A. Liposome-encapsulated statins reduce hypertrophic scarring through topical application. Wound Repair Regen., 2020, 28(4), 460-469. doi: 10.1111/wrr.12811 PMID: 32428986
  115. Yadav, M.; Schiavone, N.; Guzman-Aranguez, A.; Giansanti, F.; Papucci, L.; Perez de Lara, M.J.; Singh, M.; Kaur, I.P. Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD). Drug Deliv. Transl. Res., 2020, 10(4), 919-944. doi: 10.1007/s13346-020-00733-4 PMID: 32270439
  116. Hao, Y.; Li, W.; Zhou, X.; Yang, F.; Qian, Z. Microneedles-based transdermal drug delivery systems: A review. J. Biomed. Nanotechnol., 2017, 13(12), 1581-1597. doi: 10.1166/jbn.2017.2474 PMID: 29490749
  117. Marwah, H.; Garg, T.; Goyal, A.K.; Rath, G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv., 2016, 23(2), 564-578. doi: 10.3109/10717544.2014.935532 PMID: 25006687
  118. Ranade, V.V.; Cannon, J.B. (2011). Drug Delivery Systems (3rd ed.). CRC Press. doi: 10.1201/b10846
  119. Korani, S.; Bahrami, S.; Korani, M.; Banach, M.; Johnston, T.P.; Sahebkar, A. Parenteral systems for statin delivery: A review. Lipids Health Dis., 2019, 18(1), 193. doi: 10.1186/s12944-019-1139-8 PMID: 31690335
  120. Zhou, X.; Hao, Y.; Yuan, L.; Pradhan, S.; Shrestha, K.; Pradhan, O.; Liu, H.; Li, W. Nano-formulations for transdermal drug delivery: A review. Chin. Chem. Lett., 2018, 29(12), 1713-1724. doi: 10.1016/j.cclet.2018.10.037
  121. Lane, E. Transdermal delivery system for statin combination therapy; Google Patents, 2005.
  122. Tiwari, R.; Pathak, K. Statins therapy: A review on conventional and novel formulation approaches. J. Pharm. Pharmacol., 2011, 63(8), 983-998. doi: 10.1111/j.2042-7158.2011.01273.x PMID: 21718281
  123. Zidan, A.S.; Hosny, K.M.; Ahmed, O.A.; Fahmy, U.A. Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv., 2016, 23(5), 1536-1549. PMID: 25386740
  124. Xiang, N.; Zhou, X.; He, X.; Zhang, Y.; Zhang, J.; Zhang, Z.R.; Sun, X.; Gong, T.; Fu, Y. An injectable gel platform for the prolonged therapeutic effect of pitavastatin in the management of hyperlipidemia. J. Pharm. Sci., 2016, 105(3), 1148-1155. doi: 10.1016/j.xphs.2015.12.002 PMID: 26886326
  125. Vasnawala, H.; Kavalipati, N.; Shah, J.; Ramakrishan, A. Pleiotropic effects of statins. Indian J. Endocrinol. Metab., 2015, 19(5), 554-562. doi: 10.4103/2230-8210.163106 PMID: 26425463
  126. Liao, J.K.; Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol., 2005, 45(1), 89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748 PMID: 15822172
  127. Davies, J.T.; Delfino, S.F.; Feinberg, C.E.; Johnson, M.F.; Nappi, V.L.; Olinger, J.T.; Schwab, A.P.; Swanson, H.I. Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights, 2016, 9, LPI.S37450. doi: 10.4137/LPI.S37450 PMID: 27867302
  128. Eming, SA; Martin, P; Tomic-Canic, M Wound repair and regeneration: mechanisms, signaling, and translation. Sci. Transl. Med., 2014, 6(265), 265sr6. doi: 10.1126/scitranslmed.3009337
  129. Seto, H.; Ohba, H.; Tokunaga, K.; Hama, H.; Horibe, M.; Nagata, T. Topical administration of simvastatin recovers alveolar bone loss in rats. J. Periodontal Res., 2008, 43(3), 261-267. doi: 10.1111/j.1600-0765.2007.01024.x PMID: 18447852
  130. Moriyama, Y.; Ayukawa, Y.; Ogino, Y.; Atsuta, I.; Koyano, K. Topical application of statin affects bone healing around implants. Clin. Oral Implants Res., 2008, 19(6), 600-605. doi: 10.1111/j.1600-0501.2007.01508.x PMID: 18422989
  131. Mansour, G.; Al Ashwah, A.; Koura, A. Evaluation of simvastatin grafting around immediate dental implants in dogs. Implant Dent., 2014, 23(2), 195-199. doi: 10.1097/ID.0000000000000051 PMID: 24637528
  132. Moriyama, Y.; Ayukawa, Y.; Ogino, Y.; Atsuta, I.; Todo, M.; Takao, Y.; Koyano, K. Local application of fluvastatin improves peri-implant bone quantity and mechanical properties: A rodent study. Acta Biomater., 2010, 6(4), 1610-1618. doi: 10.1016/j.actbio.2009.10.045 PMID: 19887121
  133. Parihar, S.P.; Hartley, M.A.; Hurdayal, R.; Guler, R.; Brombacher, F. Topical simvastatin as host-directed therapy against severity of cutaneous leishmaniasis in mice. Sci. Rep., 2016, 6(1), 33458. doi: 10.1038/srep33458 PMID: 27632901
  134. Thangamani, S.; Mohammad, H.; Abushahba, M.F.N.; Hamed, M.I.; Sobreira, T.J.P.; Hedrick, V.E.; Paul, L.N.; Seleem, M.N. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci. Rep., 2015, 5(1), 16407. doi: 10.1038/srep16407 PMID: 26553420
  135. Castañeda, P.S.; Domínguez Delgado, C.L.; Cruz, I.M.R.; Contreras, L.M.M.; Trinidad, E.M.M.; Cervantes, M.L.; Escobar-Chávez, J.J. Development of poly (methyl vinyl ether-alt-maleic acid) microneedles for transdermal delivery of atorvastatin calcium. Curr. Pharm. Biotechnol., 2020, 21(9), 852-861. doi: 10.2174/1389201021666200217103302 PMID: 32065098
  136. Anod, H.V.; Gupta, N.V.; Gowda, D.V.; M, M. Preparation and evaluation of simvastatin transdermal film. Int. J. Appl. Pharm., 2018, 10(5), 235. doi: 10.22159/ijap.2018v10i5.26657
  137. Shaker, D.S.; Ishak, R.A.H.; Elhuoni, M.A.; Ghoneim, A.M. Boosting transdermal delivery of atorvastatin calcium via o/w nanoemulsifying system: Two-step optimization, ex vivo and in vivo evaluation. Int. J. Pharm., 2020, 578, 119073. doi: 10.1016/j.ijpharm.2020.119073 PMID: 31982556
  138. El Menshawe, S.F.; Nafady, M.M.; Aboud, H.M.; Kharshoum, R.M.; Elkelawy, A.M.M.H.; Hamad, D.S. Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway. Drug Deliv., 2019, 26(1), 1140-1154. doi: 10.1080/10717544.2019.1686087 PMID: 31736366
  139. Mahmoud, MO; Aboud, HM; Hassan, AH; Ali, AA; Johnston, TP Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. Journal of controlled release, 2017, 254, 10-22.
  140. Gutierrez, GE; Lalka, D; Garrett, IR; Rossini, G; Mundy, GR Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int., 2006, 17(7), 1033-1042. doi: 10.1007/s00198-006-0079-0
  141. Madi, M.; Kassem, A. Topical simvastatin gel as a novel therapeutic modality for palatal donor site wound healing following free gingival graft procedure. Acta Odontol. Scand., 2018, 76(3), 212-219. doi: 10.1080/00016357.2017.1403648 PMID: 29145771
  142. Ala, S.; Alvandipour, M.; Saeedi, M.; Hamidian, M.; Shiva, A.; Rahmani, N.; Faramarzi, F. Effects of topical atorvastatin (2%) on posthemorrhoidectomy pain and wound healing: A randomized double-blind placebo-controlled clinical trial. World J. Surg., 2017, 41(2), 596-602. doi: 10.1007/s00268-016-3749-x PMID: 27738832
  143. Farsaei, S.; Khalili, H.; Farboud, E.S.; Karimzadeh, I.; Beigmohammadi, M.T. Efficacy of topical atorvastatin for the treatment of pressure ulcers: A randomized clinical trial. Pharmacotherapy, 2014, 34(1), 19-27. doi: 10.1002/phar.1339 PMID: 23940000
  144. Joshi, R; Olver, I; Keefe, D; Marafioti, T; Smith, K. A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Supportive Care Cancer, 2007, 15(9), 1109-1112.
  145. Ahmadvand, A.; Yazdanfar, A.; Yasrebifar, F.; Mohammadi, Y.; Mahjub, R.; Mehrpooya, M. Evaluating the effects of oral and topical simvastatin in the treatment of acne vulgaris: A double-blind, randomized, placebo-controlled clinical trial. Curr. Clin. Pharmacol., 2019, 13(4), 279-283. doi: 10.2174/1574884713666180821143545 PMID: 30129417
  146. Paudel, K.S.; Milewski, M.; Swadley, C.L.; Brogden, N.K.; Ghosh, P.; Stinchcomb, A.L. Challenges and opportunities in dermal/transdermal delivery. Ther. Deliv., 2010, 1(1), 109-131. doi: 10.4155/tde.10.16 PMID: 21132122
  147. Barry, B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci., 2001, 14(2), 101-114. doi: 10.1016/S0928-0987(01)00167-1 PMID: 11500256
  148. Raza, K.; Singh, B.; Lohan, S.; Sharma, G.; Negi, P.; Yachha, Y.; Katare, O.P. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int. J. Pharm., 2013, 456(1), 65-72. doi: 10.1016/j.ijpharm.2013.08.019 PMID: 23973754
  149. Raza, K.; Katare, O.P.; Setia, A.; Bhatia, A.; Singh, B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J. Microencapsul., 2013, 30(3), 225-236. doi: 10.3109/02652048.2012.717115 PMID: 23088318
  150. Kurmi, B.D.; Tekchandani, P.; Paliwal, R.; Paliwal, S.R. Transdermal drug delivery: Opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Curr. Drug Metab., 2017, 18(5), 481-495. doi: 10.2174/1389200218666170222150555 PMID: 28228076

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers